Share

October 2013; 3 (5) Five New Things

Multiple sclerosis

Five new things

Jacqueline A. Nicholas, Aaron L. Boster, Michael K. Racke
First published October 14, 2013, DOI: https://doi.org/10.1212/CPJ.0b013e3182a78f94
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
1036

Share

This article has a correction. Please see:

Article Information

vol. 3 no. 5 404-412
DOI: 
https://doi.org/10.1212/CPJ.0b013e3182a78f94
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
2163-0402
Online ISSN: 
2163-0933
History: 
  • First Published October 14, 2013.
Copyright & Usage: 
© 2013 American Academy of Neurology

Author Disclosures

    1. Jacqueline A. Nicholas, MD, MPH,
    2. Aaron L. Boster, MD and
    3. Michael K. Racke, MD
  1. Jacqueline A. Nicholas, MD, MPH,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1)National Multiple Sclerosis Society - Sylvia Lawry 3- year Physician Fellowship Award

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Aaron L. Boster, MD and
    3. Scientific Advisory Boards:

    1. TEVA neuroscience, Biogen Idec, Questcor, Novartis, Medtronic

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Novartis, Medtronic, Genzyme, Questcor

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Serono, Novartis, Biogen Idec, Jazz, Actellion, Roche, CNS therapeutics, Teva Neuroscience, Accorda

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Michael K. Racke, MD
    4. Scientific Advisory Boards:

    1. (1) Accelerated Cure Project (2) Diogenix, Inc. (2) Revalesio, Inc. (2) Novartis

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. (1) The Neurologist, editorial board, 2005-present (2) Archives of neurology, editorial board, 2002-present (3) Journal of Neuroimmunology, Editor-in-Chief, 2010- present (4) Therapeutic Advances for Neurologic Disorders, editorial board, 2008-present

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) Novartis (2) Relavesio, Inc. (3) Mylan (4) Bioben Idec

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. (1) NINDS NS37513, PI, 1998-present (2) National Institutes of Health and Immune tolerance Network, Richard Nash, Protocol Chair, A Phase II Study of High-Dose Immunosuppressive Therapy (HDIT) Using Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) + Thymoglobulin, and Autologous CD34+ Hematopoietic Stem Cell Transplant (HCT) for the Treatment of Poor Prognosis Multiple Sclerosis, site PI, 2008-present

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. National Multiple Sclerosis Society

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. The Ohio State University Department of Neurology, Columbus.
  1. Correspondence to:
    Jacqueline.Nicholas{at}osumc.edu
View Full Text

Article usage

Article usage: October 2013 to July 2022

AbstractFullPdfSource
Oct 2013112740149Highwire
Nov 201311611218336Highwire
Dec 2013650928Highwire
Jan 2014269714Highwire
Feb 2014158926Highwire
Mar 201414345Highwire
Apr 201411308Highwire
May 201412165Highwire
Jun 20147315Highwire
Jul 20146413Highwire
Aug 20144603Highwire
Sep 20146322Highwire
Oct 201411313Highwire
Nov 20148127Highwire
Dec 20145304Highwire
Jan 20154664Highwire
Jan 201503117pmc
Feb 20153933Highwire
Feb 20150178pmc
Mar 20158824Highwire
Mar 201503113pmc
Apr 20154524Highwire
Apr 201503724pmc
May 20154818Highwire
May 201502712pmc
Jun 20153312Highwire
Jun 201501711pmc
Jul 20153700Highwire
Jul 20150195pmc
Aug 20154003Highwire
Aug 201502514pmc
Sep 20155404Highwire
Sep 20150157pmc
Oct 20154636Highwire
Oct 20150228pmc
Nov 20157213Highwire
Nov 20150226pmc
Dec 20157902Highwire
Dec 20150277pmc
Jan 20169102Highwire
Jan 20160159pmc
Feb 20166518Highwire
Feb 20160124pmc
Mar 20163216Highwire
Mar 20160126pmc
Apr 20165812Highwire
Apr 20160116pmc
May 20165104Highwire
May 20160219pmc
Jun 20165102Highwire
Jun 20160118pmc
Jul 20162816Highwire
Jul 2016098pmc
Aug 20163801Highwire
Aug 2016076pmc
Sep 20162901Highwire
Sep 20160447pmc
Oct 20162321Highwire
Oct 20160122pmc
Nov 20163431Highwire
Nov 20160115pmc
Dec 20162200Highwire
Dec 2016093pmc
Jan 20173512Highwire
Jan 20170103pmc
Feb 20172811Highwire
Feb 2017097pmc
Mar 20173602Highwire
Mar 20170212pmc
Apr 20173601Highwire
Apr 2017488pmc
May 20173300Highwire
May 201751716pmc
Jun 20171413Highwire
Jun 2017177pmc
Jul 20171500Highwire
Jul 2017144pmc
Aug 20172605Highwire
Aug 2017252pmc
Sep 20171310Highwire
Sep 2017377pmc
Oct 20172510Highwire
Oct 2017276pmc
Nov 20172510Highwire
Nov 201751315pmc
Dec 20171000Highwire
Jan 20182811Highwire
Feb 20183033Highwire
Mar 20185441Highwire
Apr 20186443Highwire
Apr 2018265pmc
May 20184442Highwire
Jun 20183500Highwire
Jun 2018067pmc
Jul 20182910Highwire
Aug 20183652Highwire
Aug 201861314pmc
Sep 20183222Highwire
Oct 20181931Highwire
Nov 20182530Highwire
Dec 20184020Highwire
Jan 20194731Highwire
Feb 20193500Highwire
Mar 20194210Highwire
Apr 20194431Highwire
May 20195810Highwire
Jun 20192822Highwire
Jul 20192210Highwire
Aug 20192010Highwire
Sep 20192321Highwire
Oct 20193600Highwire
Nov 20194631Highwire
Dec 20192910Highwire
Jan 20201310Highwire
Feb 20201930Highwire
Mar 202048220Highwire
Apr 20201791Highwire
May 20201260Highwire
Jun 202011110Highwire
Jul 2020720Highwire
Aug 202021130Highwire
Sep 20202070Highwire
Oct 20204282Highwire
Nov 202019150Highwire
Dec 20201570Highwire
Jan 20212240Highwire
Feb 20212551Highwire
Mar 20212020Highwire
Apr 2021733Highwire
May 2021500Highwire
Jun 20211331Highwire
Jul 20211210Highwire
Aug 20212411Highwire
Sep 20211352Highwire
Oct 20212790Highwire
Nov 20212400Highwire
Dec 20211901Highwire
Jan 2022911Highwire
Feb 20221640Highwire
Mar 20221660Highwire
Apr 20221421Highwire
May 20221781Highwire
Jun 20221622Highwire
Jul 2022601Highwire

The Nerve!: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

Topics Discussed

Alert Me